NORS-0791 is under clinical development by SaNOtize Research and Development and currently in Phase II for Onychomycosis (Tinea Unguium). According to GlobalData, Phase II drugs for Onychomycosis (Tinea Unguium) have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NORS-0791’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NORS-0791 is under development for the treatment of onychomycosis. It is formulated as a solution and administered by topical route. The drug candidate is a nitric oxide releasing compound and developed based on non-antibiotic platform technology.
SaNOtize Research and Development overview
SaNOtize Research and Development (Sanotize) is a biotechnology company focusing on nitric oxide releasing solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Sanotize is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of NORS-0791’s drug-specific PTSR and LoA scores, buy the report here.